Telix Pharmaceuticals signs deal to acquire QSAM Biosciences for upto $123m
MELBOURNE, AUSTRALIA: Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc. and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). The purchase price...
Telix Pharmaceuticals to acquire QSAM Biosciences and its bone cancer therapy
MELBOURNE, AUSTRALIA: Telix Pharmaceuticals Limited, an Australian company that develops radiopharmaceuticals for cancer diagnosis and treatment, has announced its intention to acquire QSAM Biosciences, Inc.,...